Kaplan Fox Investigates Medline Over FDA Warning Letters

Kaplan Fox & Kilsheimer LLP, a leading plaintiffs' securities litigation firm, is investigating potential securities violations against Medline Inc. (NASDAQ: MDLN), following a warning letter from the Federal Drug Administration (FDA). The FDA's letter, dated May 28, 2026, highlights significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, citing Medline's failure to thoroughly investigate microbial contamination incidents and inadequate cleaning practices.

On June 2, 2026, the FDA's warning letter was made public, leading to a significant drop in Medline's stock price. The stock closed at $33.19 per share, down $2.56 or 7.16% from the previous day. The FDA's action follows a similar warning letter issued in April 2026, marking the second such action in two months. According to a June 3, 2026, Reuters article, Medline has faced criticism for not adequately addressing microbial contamination issues, which the FDA claims have led to the issuance of multiple warning letters.

Kaplan Fox & Kilsheimer LLP, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, has a history of representing public pension funds, institutional investors, and businesses in complex litigation. Founded in 1956, the firm has a track record of securing large recoveries, including a $2.425 billion recovery for Bank of America shareholders in a landmark case. The firm is now encouraging Medline investors who have suffered losses due to the company's securities violations to contact them.

The investigation by Kaplan Fox is part of a broader effort to ensure that pharmaceutical companies adhere to stringent manufacturing standards. The firm's involvement suggests that Medline may face legal challenges related to its manufacturing practices, potentially impacting its reputation and financial performance. Investors are advised to monitor the situation closely, as the outcome of this investigation could have significant implications for Medline's future.